C4 Therapeutics Inc
CCCC1.420USD
-0.020-1.39%
Close 06/20, 16:00（ET）Quotes delayed by 15 min
100.81MMarket Cap
LossP/E TTM
More Details of C4 Therapeutics Inc Company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Company Info
Ticker SymbolCCCC
Company nameC4 Therapeutics Inc
IPO dateOct 02, 2020
Founded at2015
CEOMr. Andrew J. Hirsch
Number of employees110
Security typeOrdinary Share
Fiscal year-endOct 02
Address490 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02472
Phone16172310700
Websitehttps://c4therapeutics.com/
Ticker SymbolCCCC
IPO dateOct 02, 2020
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
165.12K
--
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Ms. Jolie M. Siegel, J.D.
Ms. Jolie M. Siegel, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Courtney Solberg
Ms. Courtney Solberg
Senior Manager - Investor Relations
Senior Manager - Investor Relations
--
--
Dr. Laura Bessen, M.D.
Dr. Laura Bessen, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
165.12K
--
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wasatch Global Investors Inc
10.52%
Lynx1 Capital Advisors LLC
10.00%
Soleus Capital Management, L.P.
9.83%
OrbiMed Advisors, LLC
9.62%
Betta investment Hong Kong Ltd
6.86%
Other
53.17%
Shareholders
Shareholders
Proportion
Wasatch Global Investors Inc
10.52%
Lynx1 Capital Advisors LLC
10.00%
Soleus Capital Management, L.P.
9.83%
OrbiMed Advisors, LLC
9.62%
Betta investment Hong Kong Ltd
6.86%
Other
53.17%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
27.67%
Investment Advisor
23.95%
Hedge Fund
21.97%
Private Equity
9.62%
Research Firm
7.68%
Corporation
6.86%
Individual Investor
3.25%
Bank and Trust
0.80%
Pension Fund
0.14%
Institutional Shareholding
Updated: Mon, Mar 3
Updated: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
329
73.88M
107.58%
-3.41M
2024Q4
337
73.17M
103.10%
-6.50M
2024Q3
332
72.91M
103.31%
-3.42M
2024Q2
325
69.49M
100.73%
-3.96M
2024Q1
329
66.54M
97.72%
+3.15M
2023Q4
324
51.20M
103.91%
-2.36M
2023Q3
320
38.85M
79.00%
-14.16M
2023Q2
326
38.30M
78.08%
-12.52M
2023Q1
331
41.73M
85.11%
-15.41M
2022Q4
330
43.22M
88.31%
-12.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wasatch Global Investors Inc
6.07M
8.55%
+395.23K
+6.96%
Dec 31, 2024
Lynx1 Capital Advisors LLC
6.85M
9.65%
-27.78K
-0.40%
Dec 31, 2024
Soleus Capital Management, L.P.
6.98M
9.83%
+374.95K
+5.68%
Dec 31, 2024
OrbiMed Advisors, LLC
4.38M
6.17%
--
--
Dec 31, 2024
Betta investment Hong Kong Ltd
5.57M
7.84%
+5.57M
--
Jan 04, 2024
BlackRock Institutional Trust Company, N.A.
4.88M
6.88%
+606.62K
+14.19%
Dec 31, 2024
The Vanguard Group, Inc.
3.35M
4.71%
-24.71K
-0.73%
Dec 31, 2024
Samlyn Capital, LLC
3.02M
4.25%
+3.02M
--
Dec 31, 2024
Morgan Stanley & Co. LLC
3.27M
4.61%
+1.74M
+114.38%
Dec 31, 2024
BofA Global Research (US)
1.68M
2.36%
-358.59K
-17.61%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0.01%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
